Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment

被引：0
|
作者：
Bourdette, Dennis [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA
来源：
NEUROLOGY | 2024年 / 103卷 / 06期
关键词：
D O I：
10.1212/WNL.0000000000209835
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies
    Bridge, Francesca
    Brotherton, Julia
    Stankovich, Jim
    Sanfilippo, Paul G.
    Skibina, Olga G.
    Buzzard, Katherine
    Kalincik, Tomas
    Nguyen, Ai-Lan
    Guo, Kylie
    Monif, Mastura
    Wrede, C. David
    Rath, Louise
    Taylor, Lisa
    Butzkueven, Helmut
    Jokubaitis, Vilija G.
    van der Walt, Anneke
    NEUROLOGY, 2024, 102 (04) : 1 - 13
  • [2] Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis
    Li, Jieni
    Hutton, George J.
    Varisco, Tyler J.
    Lin, Ying
    Essien, Ekere J.
    Aparasu, Rajender R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [3] Multiple sclerosis: time for early treatment with high-efficacy drugs
    Selmaj, Krzysztof
    Cree, Bruce A. C.
    Barnett, Michael
    Thompson, Alan
    Hartung, Hans-Peter
    JOURNAL OF NEUROLOGY, 2024, 271 (01) : 105 - 115
  • [4] Multiple sclerosis: time for early treatment with high-efficacy drugs
    Krzysztof Selmaj
    Bruce A. C. Cree
    Michael Barnett
    Alan Thompson
    Hans-Peter Hartung
    Journal of Neurology, 2024, 271 : 105 - 115
  • [5] Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis
    Valis, M.
    Haluskova, S.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2021, 84 (05) : 436 - 440
  • [6] Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
    Buron, Mathias Due
    Kalincik, Tomas
    Sellebjerg, Finn
    Sorensen, Per Soelberg
    Magyari, Melinda
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (05): : 556 - 562
  • [7] Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis
    Mueller, Jannis
    Roos, Izanne
    Kalincik, Tomas
    Lorscheider, Johannes
    Galli, Edoardo
    Benkert, Pascal
    Schaedelin, Sabine
    Sharmin, Sifat
    Einsiedler, Maximilian
    Haenni, Peter
    Schmid, Juerg
    Kuhle, Jens
    Derfuss, Tobias
    Granziera, Cristina
    Ziemssen, Tjalf
    Siepmann, Timo
    Yaldizli, Oezguer
    BRAIN AND BEHAVIOR, 2024, 14 (05):
  • [8] Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies
    Meca-Lallana, Jose
    Garcia-Merino, Juan Antonio
    Martinez-Yelamos, Sergio
    Vidal-Jordana, Angela
    Costa, Lucienne
    Eichau, Sara
    Rovira, Alex
    Brieva, Luis
    Aguera, Eduardo
    Zarranz, Alfredo Rodriguez-Antiguedad
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (03) : 251 - 261
  • [9] High-efficacy therapy delays disability in paediatric-onset multiple sclerosis
    Sharmin, Sifat
    Roos, Izanne
    Malpas, Charles
    Lechner-Scott, Jeannette
    Buzzard, Katherine
    Skibina, Olga
    John, Nevin
    van der Walt, Anneke
    Butzkueven, Helmut
    Barnett, Michael
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (04) : 7 - 7
  • [10] Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis
    Papukchieva, Steffeni
    Kim, Hyung-Do
    Stratil, Ann-Sophie
    Magurne, Emily
    Jonckheere, Apolline
    Kahn, Maria
    Schneeweiss, Sebastian
    Ziemssen, Tjalf
    Friedrich, Benjamin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 88
12345